Lumen Wins Grant to Develop Ultra-Low-Cost Therapeutics for Treating Infant Diseases in Developing Countries
Seattle, WA—January 5, 2018—Lumen Bioscience, a Seattle company developing novel biologics on its proprietary platform, announced today it has been awarded a grant by the Bill & Melinda Gates Foundation to support early-stage development of ultra-low-cost, easily...Recent Post
4 ideas to kick-start U.S. drug research — and beat China in biotech
Revolutionizing the Production of Biologics with Algae
Past Wilkes Prize winners accelerate audacious climate solutions
Reviewing Real-World Safety and Efficacy Data on C difficile Therapy Rebyota- Contagion Live Article on RePreve Trial